{
  "company_info": {
    "name": "AstraZeneca",
    "descriptions": [
      "A global, science-led biopharmaceutical company"
    ],
    "industries": [
      "Pharmaceuticals"
    ],
    "locations": [
      "Gothenburg"
    ],
    "skills": [
      "Machine Learning",
      "AI",
      "Data Analysis",
      "Molecular Simulations",
      "Python"
    ],
    "job_titles": [
      "Data Science and AI Student Work Placement"
    ]
  },
  "analysis": "Sammanfattning av AstraZeneca:\n\n1. Företagets storlek och anställda\n- Global, forskningsledande biofarmazeutisk företag\n- Huvudkontor i Göteborg, Sverige\n- Internationell närvaro\n\n2. Omsättning och finansiell information\n- Total intäkt 2022: $45,488 miljoner\n- Intäktsökning på 13% (exklusive COVID-19 mediciner)\n- Jämförelse tidigare år: \n  - 2020 Total intäkt: $26,617 miljoner\n  - Stadig finansiell tillväxt\n\n3. Värdegrund och kultur\n- Vetenskapligt drivet företag\n- Fokus på:\n  - Medarbetarengagemang\n  - Hållbarhet (mål att bli koldioxidnegativa till 2030)\n  - Transformation av sjukvård\n\n4. Huvudsakliga produkter/tjänster\n- Läkemedel inom viktiga medicinska områden\n- Forskningsinriktad läkemedelsutveckling\n\n5. Nyliga nyheter/utveckling\n- Fortsatt expansion inom medicinsk forskning\n- Fokus på innovation inom hälsosektorn\n\n6. Teknisk kompetens\n- Kompetensområden:\n  - Machine Learning\n  - Artificiell Intelligens\n  - Dataanalys\n  - Molekylära simuleringar\n  - Programmeringsspråk som Python\n\nKällor: AstraZeneca Annual Reports 2019-2023, webbplatsinformation",
  "search_results": [
    {
      "title": "Annual report 2022",
      "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2022.html",
      "is_source_local": false,
      "is_source_both": false,
      "description": "Science can sustain and grow the success of <strong>AstraZeneca</strong>, help us to transform the future of healthcare, and the health of people, society and the planet.",
      "profile": {
        "name": "Astrazeneca",
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2022.html",
        "long_name": "astrazeneca.com",
        "img": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw"
      },
      "language": "en",
      "family_friendly": true,
      "type": "search_result",
      "subtype": "article",
      "meta_url": {
        "scheme": "https",
        "netloc": "astrazeneca.com",
        "hostname": "www.astrazeneca.com",
        "favicon": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw",
        "path": "› investor-relations  › annual-reports  › annual-report-2022.html"
      },
      "thumbnail": {
        "src": "https://imgs.search.brave.com/Z7O8o5Gjvr7Emz5WtVn7QVNKYouEDYHRBzAZv5nf6gg/rs:fit:200:200:1:0/g:ce/aHR0cHM6Ly93d3cu/YXN0cmF6ZW5lY2Eu/Y29tL2NvbnRlbnQv/ZGFtL2F6L0ludmVz/dG9yX1JlbGF0aW9u/cy9hbm51YWwtcmVw/b3J0LTIwMjIvTmV4/dC1HZW5lcmF0aW9u/LVRoZXJhcGV1dGlj/c19MYW5kX0dyZWVu/X1JHQi1BUjIwMjIt/OTAweDUwMC5qcGc",
        "original": "https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2022/Next-Generation-Therapeutics_Land_Green_RGB-AR2022-900x500.jpg",
        "logo": false
      }
    },
    {
      "title": "Annual report 2023",
      "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2023.html",
      "is_source_local": false,
      "is_source_both": false,
      "description": "Total Revenue, excluding COVID-19 medicines, increased 13% (15% at CER) to <strong>$45,488 million</strong>. We are: maintaining employee engagement by continuing to make AstraZeneca a great place to work; protecting the planet by becoming carbon negative for all residual emissions by 2030; and advancing our ...",
      "profile": {
        "name": "Astrazeneca",
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2023.html",
        "long_name": "astrazeneca.com",
        "img": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw"
      },
      "language": "en",
      "family_friendly": true,
      "type": "search_result",
      "subtype": "article",
      "meta_url": {
        "scheme": "https",
        "netloc": "astrazeneca.com",
        "hostname": "www.astrazeneca.com",
        "favicon": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw",
        "path": "› investor-relations  › annual-reports  › annual-report-2023.html"
      },
      "thumbnail": {
        "src": "https://imgs.search.brave.com/HVkKU9hzv15gAoKzLpkCrfDLIfmXXpFGU3En081pDow/rs:fit:200:200:1:0/g:ce/aHR0cHM6Ly93d3cu/YXN0cmF6ZW5lY2Eu/Y29tL2NvbnRlbnQv/ZGFtL2F6L3doYXQt/c2NpZW5jZS1jYW4t/ZG8vQVoyMzQxLUNW/Uk0tUGxhdGludW0t/OTAweDUwMC1SR0Iu/anBn",
        "original": "https://www.astrazeneca.com/content/dam/az/what-science-can-do/AZ2341-CVRM-Platinum-900x500-RGB.jpg",
        "logo": false
      }
    },
    {
      "title": "Key facts - Our Company - AstraZeneca",
      "url": "https://www.astrazeneca.com/investor-relations/key-facts.html",
      "is_source_local": false,
      "is_source_both": false,
      "description": "Key facts about <strong>AstraZeneca</strong> - one of the world&#x27;s leading pharmaceutical <strong>companies</strong> providing effective medicines in important areas of medical need.",
      "profile": {
        "name": "Astrazeneca",
        "url": "https://www.astrazeneca.com/investor-relations/key-facts.html",
        "long_name": "astrazeneca.com",
        "img": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw"
      },
      "language": "en",
      "family_friendly": true,
      "type": "search_result",
      "subtype": "generic",
      "meta_url": {
        "scheme": "https",
        "netloc": "astrazeneca.com",
        "hostname": "www.astrazeneca.com",
        "favicon": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw",
        "path": "› investor-relations  › key-facts.html"
      },
      "thumbnail": {
        "src": "https://imgs.search.brave.com/VXQbQomE9TWVeH7qyH7V4DpJX8k7iDbtAE7mUxour-Q/rs:fit:200:200:1:0/g:ce/aHR0cHM6Ly93d3cu/YXN0cmF6ZW5lY2Eu/Y29tL2ludmVzdG9y/LXJlbGF0aW9ucy9r/ZXktZmFjdHMuaHRt/bA",
        "original": "https://www.astrazeneca.com/investor-relations/key-facts.html",
        "logo": false
      }
    },
    {
      "title": "Annual report 2020",
      "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2020.html",
      "is_source_local": false,
      "is_source_both": false,
      "description": "In 2020, Total Revenue, comprising Product Sales and Collaboration Revenue, increased by 9% (10% at CER) to <strong>$26,617 million</strong>. Product Sales grew by 10% (11% at CER) to $25,890 million. Collaboration Revenue fell by 11% (11% at CER) to $727 million.",
      "profile": {
        "name": "Astrazeneca",
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2020.html",
        "long_name": "astrazeneca.com",
        "img": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw"
      },
      "language": "en",
      "family_friendly": true,
      "type": "search_result",
      "subtype": "article",
      "meta_url": {
        "scheme": "https",
        "netloc": "astrazeneca.com",
        "hostname": "www.astrazeneca.com",
        "favicon": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw",
        "path": "› investor-relations  › annual-reports  › annual-report-2020.html"
      },
      "thumbnail": {
        "src": "https://imgs.search.brave.com/da5NGK7OcA6yePFBbrOsd4mJUvyieieY3-4wKLq1YpY/rs:fit:200:200:1:0/g:ce/aHR0cHM6Ly93d3cu/YXN0cmF6ZW5lY2Eu/Y29tL2ludmVzdG9y/LXJlbGF0aW9ucy9h/bm51YWwtcmVwb3J0/cy9hbm51YWwtcmVw/b3J0LTIwMjAuaHRt/bA",
        "original": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2020.html",
        "logo": false
      }
    },
    {
      "title": "Annual report 2019 - AstraZeneca",
      "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2019.html",
      "is_source_local": false,
      "is_source_both": false,
      "description": "// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other. *<strong>Total Revenue consists of Product Sales and Collaboration Revenue</strong>.",
      "profile": {
        "name": "Astrazeneca",
        "url": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2019.html",
        "long_name": "astrazeneca.com",
        "img": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw"
      },
      "language": "en",
      "family_friendly": true,
      "type": "search_result",
      "subtype": "article",
      "meta_url": {
        "scheme": "https",
        "netloc": "astrazeneca.com",
        "hostname": "www.astrazeneca.com",
        "favicon": "https://imgs.search.brave.com/WGI0ItqjVmHwdTUC4BST2LN6uQzTgd9K8rLRuwn1sFc/rs:fit:32:32:1:0/g:ce/aHR0cDovL2Zhdmlj/b25zLnNlYXJjaC5i/cmF2ZS5jb20vaWNv/bnMvZDBlNDQ4YmQ1/MGM3NmMyYzY1MjE0/MWEzY2QxYWRiMWRm/MmE1NzhlY2ZhMjI4/NmU2MWI3ZjJlMTRm/OTZhNmQzZi93d3cu/YXN0cmF6ZW5lY2Eu/Y29tLw",
        "path": "› investor-relations  › annual-reports  › annual-report-2019.html"
      },
      "thumbnail": {
        "src": "https://imgs.search.brave.com/TY5IcuTbqMTJseiQc4EXwfai6aJTtAwVlX0iyD1-HW4/rs:fit:200:200:1:0/g:ce/aHR0cHM6Ly93d3cu/YXN0cmF6ZW5lY2Eu/Y29tL2ludmVzdG9y/LXJlbGF0aW9ucy9h/bm51YWwtcmVwb3J0/cy9hbm51YWwtcmVw/b3J0LTIwMTkuaHRt/bA",
        "original": "https://www.astrazeneca.com/investor-relations/annual-reports/annual-report-2019.html",
        "logo": false
      }
    }
  ],
  "generated_date": "2024-11-07T02:39:10.392875"
}